Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT04541082Phase 1Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2020
- Primary completion
- Mar 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONC206 in central nervous system tumor, sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Maximum Tolerated Dose at 28 days and Number of Participants who Experienced Dose-Limiting Toxicities at 28 days. Started Oct 2020; status: recruiting.
02
Drugs
ONC206
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT04541082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541082.